Literature DB >> 28785558

Chronic Kidney Disease-Mineral and Bone Disorder in Asia.

Masafumi Fukagawa1, Hirotaka Komaba1,2.   

Abstract

BACKGROUND: Chronic kidney disease-mineral and bone disorder (CKD-MBD) is one of the most common complications in patients with CKD. As CKD-MBD is a systemic syndrome, prevention and management should be aimed at achieving better survival and less risk of cardiovascular events and fractures.
SUMMARY: Although target ranges for serum markers of mineral metabolism have been proposed in several global or local guidelines, these were mostly based on data from non-Asian patients. Additionally, there remain differences in medical and social systems as well as in economic status, even among Asian countries and areas. KEY MESSAGE: Asian CKD patient data needs to be analyzed, published, and shared to establish optimal local strategies for CKD-MBD management.

Entities:  

Keywords:  Cardiovascular events; Chronic kidney disease-mineral and bone disorder; Guideline; Parathyroid; Phosphorus calcium; Survival

Year:  2017        PMID: 28785558      PMCID: PMC5527178          DOI: 10.1159/000470909

Source DB:  PubMed          Journal:  Kidney Dis (Basel)        ISSN: 2296-9357


  55 in total

1.  Clinical significance of the K/DOQI bone guidelines in Japan.

Authors:  Keitaro Yokoyama; Naohiko Katoh; Hitoshi Kubo; Seizo Murai; Noritugu Imamura; Ryo Shoji; Hiroyasu Yamamoto; Takashi Shigematsu; Masaaki Nakayama; Shinji Takasu; Takashi Kono; Toyohiko Yoshida; Tatsuo Hosoya
Journal:  Am J Kidney Dis       Date:  2004-08       Impact factor: 8.860

2.  Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder.

Authors:  Masafumi Fukagawa; Keitaro Yokoyama; Fumihiko Koiwa; Masatomo Taniguchi; Tetsuo Shoji; Junichiro James Kazama; Hirotaka Komaba; Ryoichi Ando; Takatoshi Kakuta; Hideki Fujii; Msasaaki Nakayama; Yugo Shibagaki; Seiji Fukumoto; Naohiko Fujii; Motoshi Hattori; Akira Ashida; Kunitoshi Iseki; Takashi Shigematsu; Yusuke Tsukamoto; Yoshiharu Tsubakihara; Tadashi Tomo; Hideki Hirakata; Tadao Akizawa
Journal:  Ther Apher Dial       Date:  2013-06       Impact factor: 1.762

3.  Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.

Authors:  Masahiro Koizumi; Hirotaka Komaba; Shohei Nakanishi; Akira Fujimori; Masafumi Fukagawa
Journal:  Nephrol Dial Transplant       Date:  2011-07-05       Impact factor: 5.992

4.  Clinical outcome of twice-weekly hemodialysis patients in shanghai.

Authors:  Xinghui Lin; Yucheng Yan; Zhaohui Ni; Leyi Gu; Mingli Zhu; Huili Dai; Weiming Zhang; Jiaqi Qian
Journal:  Blood Purif       Date:  2011-12-29       Impact factor: 2.614

5.  Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism.

Authors:  Ryusei Sugimoto; Hiroshi Watanabe; Komei Ikegami; Yuki Enoki; Tadashi Imafuku; Yoshiaki Sakaguchi; Michiya Murata; Kento Nishida; Shigeyuki Miyamura; Yu Ishima; Motoko Tanaka; Kazutaka Matsushita; Hirotaka Komaba; Masafumi Fukagawa; Masaki Otagiri; Toru Maruyama
Journal:  Kidney Int       Date:  2016-12-15       Impact factor: 10.612

6.  Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.

Authors:  Francesca Tentori; Mia Wang; Brian A Bieber; Angelo Karaboyas; Yun Li; Stefan H Jacobson; Vittorio E Andreucci; Masafumi Fukagawa; Luc Frimat; David C Mendelssohn; Friedrich K Port; Ronald L Pisoni; Bruce M Robinson
Journal:  Clin J Am Soc Nephrol       Date:  2014-12-16       Impact factor: 8.237

7.  Consistent control of mineral and bone disorder in incident hemodialysis patients.

Authors:  Mark D Danese; Vasily Belozeroff; Karen Smirnakis; Kenneth J Rothman
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-02       Impact factor: 8.237

8.  Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.

Authors:  Myles Wolf; Todd A Koch; David B Bregman
Journal:  J Bone Miner Res       Date:  2013-08       Impact factor: 6.741

9.  FGF23 regulates renal sodium handling and blood pressure.

Authors:  Olena Andrukhova; Svetlana Slavic; Alina Smorodchenko; Ute Zeitz; Victoria Shalhoub; Beate Lanske; Elena E Pohl; Reinhold G Erben
Journal:  EMBO Mol Med       Date:  2014-04-06       Impact factor: 12.137

10.  A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients.

Authors:  Masafumi Fukagawa; Keitaro Yokoyama; Takashi Shigematsu; Takashi Akiba; Akifumi Fujii; Takuto Kuramoto; Motoi Odani; Tadao Akizawa
Journal:  Nephrol Dial Transplant       Date:  2017-10-01       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.